In a phase 1/2 crossover RCT of 18 patients with progressive MS, a single intrathecal dose of autologous mesenchymal stem cells did not change evoked potential latency at 6 months vs placebo (p=0.668). Fever, back pain and one case of arachnoiditis occurred.
RCTn = 18 patients
Kvistad et al. Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS)